- (survey 3.2%, prior 3.1%).
Slightly better than expected, and ahead of BOK rate decision later. Expectations for them to leave rate unchanged.
Slightly better than expected, and ahead of BOK rate decision later. Expectations for them to leave rate unchanged.
Most Popular
Sponsored
ResMed beats revenue/EPS, but market shrugs. Margin expansion seen, but costs loom. Buy RMD?
Iren & Nebius ink $B+ AI data center deals. Nebius leads in new contracts, Iren boasts larger future capacity & ARR potential.
Meta faces $3.7B nuisance suit in NM. Sweeping platform changes could force state exit, impacting future returns.
Buffett backs S&P 500 ETFs: 79% of funds lagged last year. Passive beats pros!
High-yield savings accounts offer 4%+ APY, dwarfing the 0.38% national average. Maximize earnings!
ENTG beats Q1 revenue & EPS! Margins rise on AI demand, but watch raw material costs.
IRTC beats revenue/profit estimates with 25.7% YoY growth. AI & new products drive outlook, but regulatory risks loom.
Sponsored
Must Read